Yorba Linda, Ca (PRWEB) August 28, 2017 -- Primary care physicians see more than 50 percent of myeloma patients with early symptoms, and early identification and diagnosis are essential to starting earlier treatment for multiple myeloma patients and preventing secondary complications. Participants of the webinar will learn to recognize the symptoms that myeloma patients first present to their internal medicine/family physician. They will be able to more accurately identify which lab tests are guideline-recommended for initial testing of myeloma.
The team at The Binding Site has arranged for Dr. Ola Landgren, a professor of medicine & chief of Multiple Service at Memorial Sloan-Kettering in New York City, to be the speaker for this event.
As a board-certified hematologist-oncologist Landgren will review how vague symptoms, including fatigue, bone pain, and back pain, are linked to the possibility of underlying Multiple Myeloma and what guideline-recommended tests should be used for diagnosis.
Dr. Ola Landgren is one of the world leaders in the field of early treatment strategies and molecular- and cell-based monitoring of minimal residual disease detection in Multiple Myeloma and its precursor states. As part of his ongoing research program, he is studying molecular mechanisms underlying the trajectory from precursor to full-blown Multiple Myeloma with the goal to develop treatment strategies aiming to delay, prevent, and ultimately define a cure for Multiple Myeloma.
LabRoots will host the webinar event September 21, 2017, beginning at 8:00 a.m. PDT. To learn more about the webinar, discover the continuing education credits offered, or to register for free, click here.
About Binding Site
Binding Site is committed to improving patient lives worldwide through education, collaboration and innovation. The company focuses on research, development, manufacture and distribution of innovative immunodiagnostic systems and assays for the global laboratory market. By utilizing its specialized expertize in antibody specificity technology, Binding Site has developed a broad menu of special protein assays, including the Freelite® test, the only FDA cleared and guideline-recommended serum free light chain assay on the market. Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of those patients with specific cancers and immune disorders.
For more information about Binding Site, please visit http://www.thebindingsite.com
LabRoots is the leading scientific social networking website and producer of educational virtual events and webinars. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.
Karen Sorenson, LabRoots, Inc., http://www.LabRoots.com, +1 (619) 861-0590, [email protected]